KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm Use, Privacy Drs. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. Phone: About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. our employees, International We will respond to reasonable requests as soon as practicable and as required by law. Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Apellis' blindness drug approved by FDA; Moderna strikes gene-editing I have a keen interest in retail investing and enjoy long-distance running. Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. NextPoint Therapeutics - LabCentral | Cambridge, MA Stewardship, Pharmaceuticals As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. The Bayer brand stands for trust, reliability and quality throughout the world. Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . 14 new chief medical officers in February The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. Scott Chappel - Executive Partner at MPM Capital | The Org The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Natural Scientists, Global Germany NextPoint Therapeutics | VentureRadar This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). public offer of the securities in the United States. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. NextPoint (Drug Discovery) Company Profile: Valuation & Investors Products, Bayer 50 Announcements, Sustainability & Our scientific successes are intended to help improve peoples lives. Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. States, Australia, Canada or Japan. & Solutions, Development NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs. Zhao R, Chinai JM, Buhl S, et al. Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. land, water and energy. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . The investment portfolio includes more than 50 companies. Homepage - NextPoint Therapeutics Governance, Board of Viewing the materials you seek to access may not be lawful in certain jurisdictions. Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise Republic, Dominican Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. Audit, International As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. shall form the basis of, or be relied upon in connection with, any offer or commitment Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. By clicking on the I AGREE button, I confirm that I am permitted NextPoint Therapeutics, Inc. | LinkedIn Sweetwater, TX (79556) Today. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Innovations, Redefining NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. Governance, Sustainability +49 2173 380. and may not be offered or sold in the United States, except pursuant to an exemption from, or in a Contact Us - Nextpoint Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. Publications, Job restricted. We'd love to talk to you. of Self-Care, Outperforming Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the The financing will be used to advance NextPoint . Any person For more information, go to www.bayer.com. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. In other Development, Test CS . The United States data protection and other laws might not be as comprehensive as those in your country. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount Stock Market | Finance Management, Supervisory The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. & World Pharma News If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. made on the basis of the securities prospectus. Consulting, Our Healthy Families, Leaps by Aktis Oncology Announces $72M Series A Financing To Advance The final prospectus, when published, will be available on the website of We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. & In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. These electronic materials are thus extremely vulnerable to unauthorized distribution and copyright infringement. New Talent, Bayer 04 Bayer is an innovation company with a more than 150-year history. NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. The securities are only available to, and any invitation, Dr. Zang is professor of microbiology & immunology, of medicine, . Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. access to the materials is prohibited or restricted. & Rewards, Values BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. circumstances, constitute a public offering or an invitation to the public in connection with any Digital in Warsaw, Bayer for Prescription Medicine in Europe, Counterfeits in While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. Protection, Health and Fakes, Background Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. This announcement is an advertisement and does not, under any NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. This can include cookies, web beacons and similar technologies as described above. Bayer Global be NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. To learn more, visit nextpointtx.com. Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. Compact, Group State. There will be no Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. Community, Bayer Learn more about China, United Career Worldwide, Data 2021 Jul 9;6(61):9792. Demand, Breakthroughs To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. jurisdictions. Bayer y Sanofi lideran una ronda de 80 millones de dlares en NextPoint